RecruitingNCT06073834
LUNG INFECTION in ICU (LUNG-I3)
LUNG INFECTION in ICU
Sponsor
BioMérieux
Enrollment
68 participants
Start Date
Dec 5, 2023
Study Type
OBSERVATIONAL
Conditions
Summary
objective of LUNG-I3 study is to assess the quantitative and functional differences in cells between blood and bronchoalveolar lavage (BAL) fluid after an infection, with a special focus on alveolar macrophages and neutrophils
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a new treatment for people with vap - ventilator associated pneumonia. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06073834
Related Trials
HAP/VAP Diagnosis in Critically Ill Septic Patients Using a Multiplex PCR Array
NCT059526484 locations
Physiological Effects and Safety of Continuous High-frequency Oscillatory Ventilation in Mechanical Ventilation Patients
NCT066626301 location
Efficiency and Safety of the Prolonged Use of Heat and Moisture Exchangers in ICU
NCT064106641 location
Oral Care With 3% Hydrogen Peroxide (Oroxid®) in ICU - Effects on the Lower Airway Microbial Colonisation
NCT060454291 location